Alnylam Pharmaceuticals

Latest news

• Alnylam Announces FDA Approval of Supplemental New Drug Application for Oxlumo (lumasiran) in Advanced Primary Hyperoxaluria Type 1
  7 October 2022
• FDA Approves Amvuttra (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
  13 June 2022
• Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
  4 April 2022
• Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
  21 January 2022
• Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
  24 June 2021
• Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
  19 April 2021
• Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
  7 January 2021
• FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
  24 November 2020
• Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
  7 June 2020
• Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis
  14 April 2020

Drugs Associated with Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.